Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 6/20 | 0.34 |
| ▸ | DRD2 | P14416 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032347 | 0.80 | HTR1A (0.38) | HTR1ADRD2HTR2ASIGMAR1HTR7 | |
| SCHEMBL97237 | 0.71 | TSHR (0.31) | — | |
| SCHEMBL3031813 | 0.71 | HTR1A (0.49) | HTR1ADRD2 | |
| SCHEMBL7468164 | 0.70 | — | — | |
| SCHEMBL3037839 | 0.70 | CCR8 (0.33) | — | |
| SCHEMBL9335962 | 0.68 | TSHR (0.33) | — | |
| SCHEMBL3027344 | 0.68 | CYP2D6 (0.34) | — | |
| SCHEMBL7476098 | 0.67 | — | — | |
| SCHEMBL97219 | 0.67 | — | — | |
| SCHEMBL95812 | 0.66 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | GRIN2B 2860/4885HTR1A 325/4885DRD2 189/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | GRIN2B 2853/4885HTR1A 3067/4885DRD2 3573/4885 |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | GRIN2B 3168/4885HTR1A 3437/4885DRD2 3690/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | GRIN2B 3901/4885HTR1A 3159/4885DRD2 836/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | GRIN2B 3753/4885HTR1A 343/4885DRD2 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.